Patents Assigned to ROSEMONT PHARMACEUTICALS LTD
-
Patent number: 11969503Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.Type: GrantFiled: September 9, 2021Date of Patent: April 30, 2024Assignee: Rosemont Pharmaceuticals LtdInventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
-
Patent number: 10610485Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.Type: GrantFiled: February 4, 2019Date of Patent: April 7, 2020Assignee: Rosemont Pharmaceuticals LtdInventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
-
Patent number: 10300041Abstract: Aqueous suspensions for oral administration are disclosed that include simvastatin having a d90 of simvastatin particles of less than about 100 ?m as the active agent. The aqueous suspension also includes simvastatin as about 20 mg to about 80 mg per 5 ml of the aqueous suspension, a suspending agent as about 20 mg to about 50 mg of the aqueous suspension, a wetting agent, an antimicrobial preservative, an antifoaming agent, water, and a buffering system providing the aqueous suspension with a pH of about 6.4 to about 7. Methods of making such a suspension and methods of treatments in orally administering the same are also disclosed.Type: GrantFiled: February 3, 2017Date of Patent: May 28, 2019Assignee: Rosemont Pharmaceuticals LTDInventor: Phillip Driver
-
Patent number: 10231927Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.Type: GrantFiled: November 22, 2017Date of Patent: March 19, 2019Assignee: Rosemont Pharmaceuticals Ltd.Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
-
Patent number: 9855215Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.Type: GrantFiled: February 9, 2016Date of Patent: January 2, 2018Assignee: Rosemont Pharmaceuticals Ltd.Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
-
Patent number: 9597289Abstract: A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 ?m in diameter. The present invention also includes uses of the suspension and methods of making the suspension.Type: GrantFiled: April 26, 2007Date of Patent: March 21, 2017Assignee: ROSEMONT PHARMACEUTICALS LTD.Inventor: Phillip Driver
-
Patent number: 9259427Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.Type: GrantFiled: January 2, 2013Date of Patent: February 16, 2016Assignee: Rosemont Pharmaceuticals LTDInventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
-
Publication number: 20130178476Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.Type: ApplicationFiled: January 2, 2013Publication date: July 11, 2013Applicant: ROSEMONT PHARMACEUTICALS LTDInventor: ROSEMONT PHARMACEUTICALS LTD